Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Nov;38(11):1219-1236.
doi: 10.1007/s40273-020-00952-0.

A Systematic Review of Medical Costs Associated with Heart Failure in the USA (2014-2020)

Michael Urbich  1 , Gary Globe  2 , Krystallia Pantiri  3 , Marieke Heisen  3 , Craig Bennison  4 , Heidi S Wirtz  2 , Gian Luca Di Tanna  5
Affiliations

A Systematic Review of Medical Costs Associated with Heart Failure in the USA (2014-2020)

Michael Urbich et al. Pharmacoeconomics. 2020 Nov.

Abstract

Background: Heart failure presents a growing clinical and economic burden in the USA. Robust cost data on the burden of illness are critical to inform economic evaluations of new therapeutic interventions.

Objectives: This systematic literature review of heart failure-related costs in the USA aimed to assess the quality of the published evidence and provide a narrative synthesis of current data.

Methods: Four electronic databases (MEDLINE, EMBASE, EconLit, and the Centre for Reviews and Dissemination York Database, including the NHS Economic Evaluation Database and Health Technology Assessment Database) were searched for journal articles published between January 2014 and March 2020. The review, registered with PROSPERO (CRD42019134201), was restricted to cost-of-illness studies in adults with heart failure events in the USA.

Results: Eighty-seven studies were included, 41 of which allowed a comparison of cost estimates across studies. The annual median total medical costs for heart failure care were estimated at $24,383 per patient, with heart failure-specific hospitalizations driving costs (median $15,879 per patient). Analyses of subgroups revealed that heart failure-related costs are highly sensitive to individual patient characteristics (such as the presence of comorbidities and age) with large variations even within a subgroup. Additionally, differences in study design and a lack of standardized reporting limited the ability to compare cost estimates. The finding that costs are higher for patients with heart failure with reduced ejection fraction compared with patients with preserved ejection fraction highlights the need for differentiating among different heart failure types.

Conclusions: The review underpins the conclusion drawn in earlier reviews, namely that hospitalization costs are the key driver of heart failure-related costs. Analyses of subgroups provide a clearer understanding of sources of heterogeneity in cost data. While current cost estimates provide useful indications of economic burden, understanding the nuances of the data is critical to support its application.

PubMed Disclaimer

Conflict of interest statement

Michael Urbich, Gary Globe, and Heidi S. Wirtz are employees of Amgen and hold corporate stock in Amgen. Heidi S. Wirtz also holds corporate stock in Teva Pharmaceutical Industries Ltd. Krystallia Pantiri, Marieke Heisen, and Craig Bennison report funding from Amgen Inc. to Pharmerit International, during the conduct of the study; employment from Pharmerit International, outside the submitted work. Gian Luca Di Tanna was an employee of Amgen until February 2019. He received an honoraria fee from Amgen during the conduct of the study for providing methodological support.

Figures

Fig. 1
Fig. 1
Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flowchart displaying the number of publications included as well as the number of publications that were excluded, with reasons. CRD Centre for Reviews and Dissemination, HF heart failure, HTA health technology assessment, NHS EED NHS Economic Evaluation Database, SLR systematic literature review
Fig. 2
Fig. 2
Quality assessment of costing methodology of the studies. †Abstract
See this image and copyright information in PMC

References

    1. GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1789–858. 10.1016/s0140-6736(18)32279-7. - PMC - PubMed
    1. Benjamin EJ, Virani SS, Callaway CW, Chamberlain AM, Chang AR, Cheng S, et al. Heart disease and stroke statistics: 2018 update: a report from the American Heart Association. Circulation. 2018;137(12):E67–E92. doi: 10.1161/CIR.0000000000000558. - DOI - PubMed
    1. Heidenreich PA, Albert NM, Allen LA, Bluemke DA, Butler J, Fonarow GC, et al. Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. Circ Heart Fail. 2013;6(3):606–619. doi: 10.1161/HHF.0b013e318291329a. - DOI - PMC - PubMed
    1. Crespo-Leiro MG, Anker SD, Maggioni AP, Coats AJ, Filippatos G, Ruschitzka F, et al. European Society of Cardiology Heart Failure Long-Term Registry (ESC-HF-LT): 1-year follow-up outcomes and differences across regions. Eur J Heart Fail. 2016;18(6):613–625. doi: 10.1002/ejhf.566. - DOI - PubMed
    1. Greene SJ, Butler J, Albert NM, DeVore AD, Sharma PP, Duffy CI, et al. Medical therapy for heart failure with reduced ejection fraction: the CHAMP-HF Registry. J Am Coll Cardiol. 2018;72(4):351–366. doi: 10.1016/j.jacc.2018.04.070. - DOI - PubMed

Publication types